by Elana Gotkine For patients with relapsing multiple sclerosis, the anti-CD40L monoclonal antibody frexalimab has a favorable effect on the number of new gadolinium-enhancing T1-weighted lesions, according to a study published in the Feb. 15 issue of the New England Journal of Medicine.Patrick Vermersch, M.D., Ph.D., from the University of Lille in France, and colleagues...
